iron profile

taconite: iron ore which also contains quartz & silicates; has adverse effects similar to asbestos & silicon [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Pathways (491)

iron is involved in 491 pathway(s), involving a total of 21066 unique proteins and 18440 unique compounds

ID Source	ID
PubMed CID	27284
CHEBI ID	29033
MeSH ID	M0011718

Synonym
iron ion(2+)
CHEBI:29033
iron(2+) ion
iron(ii) cation
iron(2+)ions
iron ion (2+)
iron, ion(fe 2+)
iron (fe 2+)
iron (ii) ion
fe++
iron divalent ion
ferrous cation
ferrous ions
ferrous
iron dication
iron(2+) ions
fe(ii)
iron(ii)
ferrous ion
FE+2 ,
fe2+
feii
iron(2+)
15438-31-0
fe(2+)
infed
fe +2
unii-gw89581owr
gw89581owr ,
iron, ion (fe2+)
taconite
limonite
iron(ii) ion
iron (ii)
CWYNVVGOOAEACU-UHFFFAOYSA-N
fe +2 ion
DTXSID4042672
wrought iron
malleable iron
DB14510
Q428946
pyrite8137

Role	Description
human metabolite	Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metabolite	Any fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metabolite	Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
cofactor	An organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
iron cation
monoatomic dication
divalent metal cation	A metal cation with a valence of two.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Transport of small molecules	392	95
SLC-mediated transmembrane transport	135	67
Transport of bile salts and organic acids, metal ions and amine compounds	49	28
Metal ion SLC transporters	14	7
Iron uptake and transport	29	19
Transferrin endocytosis and recycling	10	7
Developmental Biology	727	30
Extracellular matrix organization	135	20
Collagen formation	19	14
Collagen biosynthesis and modifying enzymes	8	9
Metabolism	1496	1108
Inositol phosphate metabolism	32	35
Synthesis of IP2, IP, and Ins in the cytosol	5	17
Metabolism of lipids	500	463
Fatty acid metabolism	113	203
Arachidonic acid metabolism	36	82
Synthesis of Leukotrienes (LT) and Eoxins (EX)	13	29
Synthesis of 5-eicosatetraenoic acids	6	15
Synthesis of 15-eicosatetraenoic acid derivatives	3	14
Synthesis of 12-eicosatetraenoic acid derivatives	4	12
Synthesis of Hepoxilins (HX) and Trioxilins (TrX)	1	4
Peroxisomal lipid metabolism	25	52
Alpha-oxidation of phytanate	6	25
Sphingolipid metabolism	55	50
Sphingolipid de novo biosynthesis	17	16
Metabolism of steroids	111	135
Bile acid and bile salt metabolism	31	71
Synthesis of bile acids and bile salts	20	68
Biosynthesis of specialized proresolving mediators (SPMs)	13	107
Synthesis of Lipoxins (LX)	6	16
Biosynthesis of DHA-derived SPMs	11	56
Biosynthesis of DPA-derived SPMs	4	19
Biosynthesis of DPAn-6 SPMs	2	4
Biosynthesis of DPAn-3 SPMs	4	17
Biosynthesis of DPAn-3-derived maresins	2	10
Nucleotide metabolism	89	125
Nucleotide biosynthesis	12	46
Purine ribonucleoside monophosphate biosynthesis	9	36
Metabolism of vitamins and cofactors	146	155
Metabolism of fat-soluble vitamins	26	23
Retinoid metabolism and transport	22	17
Metabolism of cofactors	19	47
Ubiquinol biosynthesis	8	24
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation	10	25
Amino acid and derivative metabolism	250	260
Carnitine synthesis	4	16
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism	44	85
Phenylalanine and tyrosine catabolism	11	31
Tryptophan catabolism	14	26
Methionine salvage pathway	6	16
Metabolism of amine-derived hormones	14	40
Catecholamine biosynthesis	4	18
Serotonin and melatonin biosynthesis	3	15
Sulfur amino acid metabolism	27	63
Degradation of cysteine and homocysteine	15	38
Porphyrin metabolism	23	44
Heme biosynthesis	15	30
Heme degradation	10	21
Biological oxidations	150	276
Phase I - Functionalization of compounds	69	175
Cytochrome P450 - arranged by substrate type	30	110
Mitochondrial iron-sulfur cluster biogenesis	11	11
DNA Repair	255	47
DNA Damage Reversal	8	10
Reversal of alkylation damage by DNA dioxygenases	7	9
ALKBH2 mediated reversal of alkylation damage	1	7
ALKBH3 mediated reversal of alkylation damage	4	7
Signaling Pathways	1269	117
Signaling by GPCR	249	55
GPCR downstream signalling	172	52
G alpha (i) signalling events	87	41
Opioid Signalling	23	19
DARPP-32 events	7	11
Visual phototransduction	62	41
Cellular responses to stimuli	483	56
Cellular responses to stress	469	54
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha	55	6
Cellular Senescence	84	9
Oxidative Stress Induced Senescence	25	7
Cell Cycle	538	31
Cell Cycle, Mitotic	410	31
M Phase	279	21
Mitotic Prophase	62	14
Condensation of Prophase Chromosomes	13	10
Events associated with phagocytolytic activity of PMN cells	2	13
Porphyrin Metabolism	16	36
Acute Intermittent Porphyria	16	36
Porphyria Variegata (PV)	16	36
Congenital Erythropoietic Porphyria (CEP) or Gunther Disease	16	36
Hereditary Coproporphyria (HCP)	16	36
Biosynthesis of Siderophore Group Nonribosomal Peptides	18	21
Metabolism of proteins	1058	144
Post-translational protein modification	666	112
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	46	26
Hypusinylation	2	8
Disease	1278	231
Disorders of transmembrane transporters	102	43
SLC transporter disorders	45	37
Defective CP causes aceruloplasminemia (ACERULOP)	1	4
Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1)	0	2
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages)	1	2
Diseases of metabolism	69	121
Phenylketonuria	1	4
Infectious disease	895	79
Latent infection of Homo sapiens with Mycobacterium tuberculosis	32	32
Latent infection - Other responses of Mtb to phagocytosis	32	33
Tolerance of reactive oxygen produced by macrophages	11	8
Mtb iron assimilation by chelation	6	10
Gene expression (Transcription)	902	49
reactive oxygen species degradation	0	11
superpathway of proto- and siroheme biosynthesis	16	38
Epigenetic regulation of gene expression	117	17
Oxidative demethylation of DNA	4	9
Immune System	914	82
Innate Immune System	414	75
ROS and RNS production in phagocytes	12	37
Metabolism of RNA	637	40
tRNA processing	107	29
tRNA modification in the nucleus and cytosol	43	25
Synthesis of wybutosine at G37 of tRNA(Phe)	6	16
stachyose biosynthesis	5	23
superpathway of plastoquinol biosynthesis	3	18
methyl indole-3-acetate interconversion	2	12
quercetin gentiotetraside biosynthesis	3	17
isoflavonoid biosynthesis II	1	24
gossypetin metabolism	0	25
vitamin E biosynthesis (tocopherols)	0	17
heme b biosynthesis I (aerobic)	6	12
(S)-reticuline biosynthesis I	0	30
suberin monomers biosynthesis	10	36
chrysin biosynthesis	1	12
eupatolitin 3-O-glucoside biosynthesis	0	30
luteolin biosynthesis	6	15
kaempferol gentiobioside biosynthesis	3	17
glucosinolate activation	1	15
polymethylated quercetin glucoside biosynthesis I - quercetin series (Chrysosplenium)	2	26
coniferyl alcohol 9-methyl ester biosynthesis	2	8
hyperforin and adhyperforin biosynthesis	0	13
superpathay of heme b biosynthesis from glutamate	11	28
gibberellin biosynthesis II (early C-3 hydroxylation)	4	15
Fe(II)-nicotianamine transport in phloem	1	2
coumarins biosynthesis (engineered)	6	28
rosmarinic acid biosynthesis II	0	23
5-deoxystrigol biosynthesis	3	10
superpathway of betalain biosynthesis	2	41
flavonol glucosylation I	1	18
superpathway of rosmarinic acid biosynthesis	1	40
myricetin gentiobioside biosynthesis	3	16
hydroxycinnamic acid tyramine amides biosynthesis	0	21
lupanine biosynthesis	0	17
siroheme biosynthesis	1	11
polymethylated quercetin glucoside biosynthesis II - quercetagetin series (Chrysosplenium)	2	31
iron reduction and absorption	12	5
volatile cinnamoic ester biosynthesis	0	16
berberine biosynthesis	0	32
betalamic acid biosynthesis	1	14
phytate degradation I	3	16
plastoquinol-9 biosynthesis I	0	13
superpathway of polymethylated quercetin/quercetagetin glucoside biosynthesis (Chrysosplenium)	2	34
(-)-4'-demethyl-epipodophyllotoxin biosynthesis	1	11
superpathway of anaerobic sucrose degradation	33	60
sucrose degradation II (sucrose synthase)	17	22
Phenylalanine and tyrosine metabolism	11	32
Phenylalanine metabolism	6	21
Tyrosine catabolism	5	15
Infection with Mycobacterium tuberculosis	74	42
Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway	0	16
Bloch Pathway (Cholesterol Biosynthesis)	9	29
Kandutsch-Russell Pathway (Cholesterol Biosynthesis)	9	30
phytochromobilin biosynthesis	1	7
morphine biosynthesis	2	34
heme degradation I	0	14
vindoline, vindorosine and vinblastine biosynthesis	2	40
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-2	0	490
HMOX1 pathway (COVID-19 Disease Map)	36	30
Electron Transport Chain (COVID-19 Disease Map)	11	20
3q29 copy number variation syndrome	0	12
Riboflavin and CoQ disorders	16	27
Cellular response to chemical stress	167	40
Cytoprotection by HMOX1	34	19
Sensory Perception	215	68
Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway	1	6
Alzheimer's disease	2	11
superpathway of heme b biosynthesis from glutamate	0	22
Bacterial Infection Pathways	123	47
11p11.2 copy number variation syndrome	2	16
Iron metabolism disorders	0	4
Protein hydroxylation	20	5
Maternal to zygotic transition (MZT)	60	17
Chromatin modifications during the maternal to zygotic transition (MZT)	14	9
NAD de novo biosynthesis	12	33
heme biosynthesis from uroporphyrinogen-III I	4	13
heme biosynthesis	9	20
tryptophan degradation	13	45
L-kynurenine degradation	13	52
superpathway of tryptophan utilization	42	92
tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde	7	22
fatty acid u03B1-oxidation	4	17
tyrosine degradation	5	17
polymethylated quercetin glucoside biosynthesis I - quercetin series (Chrysosplenium)	2	31
myricetin gentiobioside biosynthesis	3	17
NAD/NADP-NADH/NADPH cytosolic interconversion (yeast)	5	26
vindoline and vinblastine biosynthesis	6	35
superpathway NAD/NADP - NADH/NADPH interconversion (yeast)	10	31
polymethylated quercetin glucoside biosynthesis II - quercetagetin series (Chrysosplenium)	2	38
ethylene glycol degradation	2	9
(S)-propane-1,2-diol degradation	6	18
superpathway of glycol metabolism and degradation	10	35
pentachlorophenol degradation	4	25
5-aminoimidazole ribonucleotide biosynthesis I	12	38
2-nitrobenzoate degradation I	7	23
procollagen hydroxylation and glycosylation	9	14
ammonia assimilation cycle III	4	33
cytidine-5'-diphosphate-glycerol biosynthesis	3	15
ethylene biosynthesis IV (engineered)	2	18
rosmarinic acid biosynthesis II	1	22
N-acetylneuraminate and N-acetylmannosamine degradation I	4	16
thiosulfate disproportionation II (cytochrome)	1	9
heme b biosynthesis II (anaerobic)	4	13
anthranilate degradation I (aerobic)	7	8
heme b biosynthesis IV (Gram-positive bacteria)	3	14
superpathay of heme b biosynthesis from glutamate	20	47
superpathway of heme b biosynthesis from uroporphyrinogen-III	5	17
superpathway of b heme biosynthesis from glycine	10	46
heme b biosynthesis I (aerobic)	14	28
2-keto-L-gulonate biosynthesis	4	17
colanic acid building blocks biosynthesis	9	49
morphine biosynthesis	5	36
berberine biosynthesis	1	32
retinol biosynthesis	13	9
2-aminoethylphosphonate degradation III	2	10
spermidine biosynthesis I	6	35
CMP-N-acetylneuraminate biosynthesis I (eukaryotes)	7	38
poly(3-O-u03B2-D-glucopyranosyl-N-acetylgalactosamine 1-phosphate) wall teichoic acid biosynthesis	12	33
methyl indole-3-acetate interconversion	0	13
indole-3-acetate biosynthesis IV (bacteria)	0	7
L-tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde	12	22
scopoletin biosynthesis	5	15
suberin monomers biosynthesis	13	42
umbelliferone biosynthesis	1	14
esculetin biosynthesis	1	9
coumarins biosynthesis (engineered)	8	31
photosynthetic 3-hydroxybutanoate biosynthesis (engineered)	63	73
autoinducer AI-2 biosynthesis I	3	19
autoinducer AI-2 biosynthesis II (Vibrio)	2	13
L-glutamine degradation II	4	18
superpathway of the 3-hydroxypropanoate cycle	16	34
3-hydroxypropanoate cycle	13	29
superpathway of pyrimidine deoxyribonucleosides degradation	7	38
superpathway of L-phenylalanine biosynthesis	16	65
stachyose biosynthesis	3	23
isoflavonoid biosynthesis II	1	28
stipitatate biosynthesis	4	24
eugenol and isoeugenol biosynthesis	8	13
volatile cinnamoic ester biosynthesis	2	16
12-epi-hapalindole biosynthesis	5	15
t-anethole biosynthesis	2	15
superpathway of rosmarinic acid biosynthesis	2	43
paerucumarin biosynthesis	2	12
D-galactarate degradation I	5	30
ethanol degradation I	4	15
atrazine degradation I (aerobic)	4	13
ethanolamine utilization	13	36
superpathway of L-lysine degradation	33	112
coenzyme M biosynthesis I	5	28
L-lysine degradation IV	0	39
L-lysine degradation III	1	26
superpathway of N-acetylglucosamine, N-acetylmannosamine and N-acetylneuraminate degradation	9	24
violacein biosynthesis	5	20
aromatic biogenic amine degradation (bacteria)	3	35
rhabduscin biosynthesis	3	13
L-tyrosine degradation I	10	23
L-lysine degradation IX	0	15
hapalindole H biosynthesis	6	14
aflatoxins B1 and G1 biosynthesis	2	18
curcumin degradation	1	17
anditomin biosynthesis	12	35
superpathway of dimethylsulfone degradation	2	19
5-deoxystrigol biosynthesis	3	11
3-amino-5-hydroxybenzoate biosynthesis	3	24
superpathway of microbial D-galacturonate and D-glucuronate degradation	35	92
L-glutamate and L-glutamine biosynthesis	14	42
heme degradation V	2	13
heme degradation VI	2	8
heme degradation III	1	9
2,4-dinitrotoluene degradation	7	20
serotonin and melatonin biosynthesis	7	17
heme degradation VII	1	8
heme degradation II	3	8
catecholamine biosynthesis	3	28
heme degradation I	3	14
2-oxobutanoate degradation I	10	28
L-asparagine degradation I	4	25
superpathway of purine deoxyribonucleosides degradation	6	37
flavin biosynthesis II (archaea)	8	28
L-carnitine degradation III	7	24
sulfur oxidation II (Fe+3-dependent)	0	16
superpathway of purine nucleotides de novo biosynthesis I	36	49
dTDP-N-acetylviosamine biosynthesis	2	16
chrysophanol biosynthesis	0	7
4-hydroxyacetophenone degradation	5	20
methylgallate degradation	11	22
carbazole degradation	6	11
superpathway of nicotinate degradation	12	54
3-methylquinoline degradation	0	16
5,5'-dehydrodivanillate degradation	5	16
noradrenaline and adrenaline degradation	8	23
S-methyl-5-thio-u03B1-D-ribose 1-phosphate degradation I	13	20
L-lysine fermentation to acetate and butanoate	8	57
4-amino-3-hydroxybenzoate degradation	2	40
terephthalate degradation	4	10
superpathway of aromatic compound degradation via 2-hydroxypentadienoate	50	95
mixed acid fermentation	32	76
stephacidin A biosynthesis	2	17
purine nucleobases degradation I (anaerobic)	2	40
purine nucleobases degradation II (anaerobic)	0	51
phytate degradation I	0	21
superpathway of aromatic compound degradation via 3-oxoadipate	36	81
2-aminophenol degradation	9	21
3-phenylpropanoate and 3-(3-hydroxyphenyl)propanoate degradation	11	22
6-hydroxymethyl-dihydropterin diphosphate biosynthesis II (Methanocaldococcus)	4	17
heparin degradation	3	15
chondroitin sulfate degradation I (bacterial)	4	13
benzene degradation	4	11
2,5-xylenol and 3,5-xylenol degradation	4	27
superpathway of demethylmenaquinol-8 biosynthesis I	11	33
nitrilotriacetate degradation	2	22
syringate degradation	12	24
2-amino-3-carboxymuconate semialdehyde degradation to glutaryl-CoA	2	26
vitamin E biosynthesis (tocopherols)	5	18
superpathway of N-acetylneuraminate degradation	39	79
nicotine degradation II (pyrrolidine pathway)	10	34
nicotine degradation III (VPP pathway)	10	32
norspermidine biosynthesis	7	25
superpathway of polyamine biosynthesis I	7	59
superpathway of polyamine biosynthesis III	7	28
pyrimidine ribonucleosides salvage III	6	13
phycoerythrobilin biosynthesis II	0	9
ammonia oxidation III	0	16
ammonia oxidation IV (autotrophic ammonia oxidizers)	7	24
superpathway of arginine and polyamine biosynthesis	18	101
ammonia oxidation I (aerobic)	9	24
meso-butanediol biosynthesis I	2	6
nicotinate degradation III	12	41
phycoviolobilin biosynthesis	4	9
glycerol degradation III	6	13
nicotinate degradation I	8	33
luteolin biosynthesis	3	16
phycoerythrobilin biosynthesis I	3	10
phycourobilin biosynthesis	4	10
phytochromobilin biosynthesis	4	9
pyrimidine nucleobases salvage II	4	18
phycocyanobilin biosynthesis	5	9
4-amino-2-methyl-5-diphosphomethylpyrimidine biosynthesis (yeast)	7	29
kanamycin biosynthesis	10	42
superpathway of rifamycin B biosynthesis	13	54
photosynthesis light reactions	147	8
novobiocin biosynthesis	17	41
validamycin biosynthesis	10	34
fatty acid u03B1-oxidation II	7	18
fosfomycin biosynthesis	4	26
caffeine degradation III (bacteria, via demethylation)	5	21
superpathway of penicillin, cephalosporin and cephamycin biosynthesis	11	69
starch degradation III	1	15
L-valine biosynthesis	16	34
deacetylcephalosporin C biosynthesis	4	44
sulfur disproportionation II (aerobic)	1	12
FR-900098 and FR-33289 antibiotics biosynthesis	7	26
neopentalenoketolactone and pentalenate biosynthesis	7	25
streptomycin biosynthesis	4	52
CDP-D-arabitol biosynthesis	2	15
taurine biosynthesis I	4	20
CDP-D-mannitol biosynthesis	2	12
glycogen degradation I	8	50
3-[(E)-2-isocyanoethenyl]-1H-indole biosynthesis	2	12
L-histidine biosynthesis	18	33
L-methionine salvage cycle I (bacteria and plants)	19	38
gentisate degradation II	3	11
pectin degradation I	3	11
UDP-N-acetyl-D-glucosamine biosynthesis II	23	33
phosphinothricin tripeptide biosynthesis	19	56
D-galactose degradation I (Leloir pathway)	10	46
lincomycin biosynthesis	3	16
L-threonine degradation IV	4	15
L-arginine biosynthesis I (via L-ornithine)	11	53
dehydrophos biosynthesis	10	25
L-threonine degradation II	3	31
L-threonine degradation III (to methylglyoxal)	3	28
lupanine biosynthesis	0	19
meta cleavage pathway of aromatic compounds	14	22
superpathway of aromatic amino acid biosynthesis	21	84
protocatechuate degradation I (meta-cleavage pathway)	15	29
protocatechuate degradation III (para-cleavage pathway)	5	15
D-glucuronate degradation I	2	21
dimethyl sulfide degradation I	2	17
superpathway of u03B2-D-glucuronosides degradation	11	36
cob(II)yrinate a,c-diamide biosynthesis II (late cobalt incorporation)	14	44
superpathway of cholesterol degradation II (cholesterol dehydrogenase)	30	58
hyperforin and adhyperforin biosynthesis	0	18
superpathway of cholesterol degradation I (cholesterol oxidase)	17	55
3-phenylpropanoate and 3-(3-hydroxyphenyl)propanoate degradation to 2-hydroxypentadienoate	8	15
superpathway of sulfur oxidation (Acidianus ambivalens)	3	22
chorismate biosynthesis I	15	59
superpathway of acrylonitrile degradation	0	10
mercaptosuccinate degradation	1	9
glyoxylate assimilation	11	31
CMP-8-amino-3,8-dideoxy-D-manno-octulosonate biosynthesis	3	19
superoxide radicals degradation	9	14
superpathway of CMP-sialic acids biosynthesis	14	60
sucrose degradation II (sucrose synthase)	13	20
L-glutamate biosynthesis I	2	12
flaviolin dimer and mompain biosynthesis	6	22
glycolysis V (Pyrococcus)	7	30
L-lactaldehyde degradation (anaerobic)	2	9
catechol degradation to 2-hydroxypentadienoate II	4	12
L-rhamnose degradation II	6	23
catechol degradation to 2-hydroxypentadienoate I	2	8
catechol degradation II (meta-cleavage pathway)	8	19
L-cysteine degradation I	2	14
catechol degradation I (meta-cleavage pathway)	8	17
L-ornithine biosynthesis I	6	34
siroheme biosynthesis	8	11
siroheme amide biosynthesis	1	11
2-carboxy-1,4-naphthoquinol biosynthesis	21	29
glycogen biosynthesis I (from ADP-D-Glucose)	4	25
androstenedione degradation	34	39
superpathway of dTDP-glucose-derived O-antigen building blocks biosynthesis	28	36
superpathway of L-tyrosine biosynthesis	15	57
superpathway of menaquinol-8 biosynthesis I	10	36
plastoquinol-9 biosynthesis I	0	14
superpathway of plastoquinol biosynthesis	1	19
L-arginine degradation VIII (arginine oxidase pathway)	3	25
superpathway of chorismate metabolism	56	186
gallate degradation I	10	15
gallate degradation III (anaerobic)	1	30
toluene degradation IV (aerobic) (via catechol)	16	25
UDP-u03B1-D-glucose biosynthesis I	14	24
superpathway of D-glucarate and D-galactarate degradation	6	37
superpathway of taurine degradation	6	37
superpathway of fucose and rhamnose degradation	11	41
L-tryptophan degradation III (eukaryotic)	17	45
reactive oxygen species degradation	7	17
L-ascorbate biosynthesis V	1	27
lipoate biosynthesis and incorporation II	2	11
superpathway of glycerol degradation to 1,3-propanediol	8	26
superpathway of UDP-glucose-derived O-antigen building blocks biosynthesis	11	39
Fe(II) oxidation	9	11
pentose phosphate pathway	9	29
superpathway of atrazine degradation	7	18
iron reduction and absorption	5	4
aminopropanol phosphate biosynthesis II	3	28
oleate biosynthesis II (animals and fungi)	4	8
pentose phosphate pathway (non-oxidative branch)	6	19
D-galacturonate degradation I	5	27
D-fructuronate degradation	8	29
superpathway of betalain biosynthesis	2	52
betalamic acid biosynthesis	2	14
superpathway of hexuronide and hexuronate degradation	8	38
superpathway of sulfide oxidation (Acidithiobacillus ferrooxidans)	2	26
superpathway of L-tryptophan biosynthesis	16	65
ginsenosides biosynthesis	10	32
superpathway of L-threonine metabolism	21	72
anthocyanin biosynthesis (pelargonidin 3-O-glucoside)	2	13
L-carnitine biosynthesis	6	23
anthocyanin biosynthesis	2	9
superpathway of anaerobic sucrose degradation	26	61
gibberellin inactivation II (methylation)	2	16
superpathway of aerobic toluene degradation	38	47
3-chlorocatechol degradation III (meta pathway)	1	11
(S)-reticuline biosynthesis I	1	28
2,4,5-trichlorophenoxyacetate degradation	6	22
2,4-dichlorophenoxyacetate degradation	3	14
coniferyl alcohol 9-methyl ester biosynthesis	2	9
epoxypseudoisoeugenol-2-methylbutanoate biosynthesis	2	22
L-tryptophan degradation XI (mammalian, via kynurenine)	13	56
glucose and glucose-1-phosphate degradation	4	34
2'-deoxy-u03B1-D-ribose 1-phosphate degradation	4	28
oxygenic photosynthesis	71	28
glucosinolate activation	3	7
aromatic glucosinolate activation	1	11
trehalose biosynthesis V	5	7
ergothioneine biosynthesis I (bacteria)	5	22
ergothioneine biosynthesis II (fungi)	2	15
superpathway of gibberellin biosynthesis	23	39
4-toluenesulfonate degradation I	6	14
superpathway of L-methionine salvage and degradation	28	69
ethylene biosynthesis II (microbes)	1	19
ethylene biosynthesis III (microbes)	0	15
ethylene biosynthesis V (engineered)	78	42
pyruvate fermentation to ethanol I	10	20
3-dehydroquinate biosynthesis I	5	31
L-isoleucine biosynthesis II	14	30
S-adenosyl-L-methionine cycle I	4	17
nitrifier denitrification	14	25
NAD de novo biosynthesis II (from tryptophan)	18	35
eupatolitin 3-O-glucoside biosynthesis	0	31
3-dimethylallyl-4-hydroxybenzoate biosynthesis	3	14
superpathway of polymethylated quercetin/quercetagetin glucoside biosynthesis (Chrysosplenium)	2	46
taurine degradation IV	1	16
quercetin gentiotetraside biosynthesis	3	19

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (11.11)	18.7374
1990's	1 (2.78)	18.2507
2000's	13 (36.11)	29.6817
2010's	14 (38.89)	24.3611
2020's	4 (11.11)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (7.69%)	6.00%
Case Studies	2 (5.13%)	4.05%
Observational	0 (0.00%)	0.25%
Other	34 (87.18%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (179)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase III, Randomised, Open-label, Comparative Safety and Efficacy Trial of Intravenous Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®) and Iron Sucrose in Subjects With Iron Deficiency Anemia (FERWON-IDA)[NCT02940886]	Phase 3	1,512 participants (Actual)	Interventional	2016-11-08	Completed
Is Iron Supplementation Harmful in Populations Where Iron Deficiency is Not the Cause of Anemia? A 12 Week Randomized Controlled Trial in Cambodia[NCT04017598]	Phase 4	480 participants (Actual)	Interventional	2019-12-10	Active, not recruiting
To Compare the Efficacy of I.V 200 mg Iron Sucrose and 500 mg Iron Sucrose to Treat Anemia in Pregnancy[NCT02441439]		0 participants (Actual)	Interventional	2022-01-01	Withdrawn(stopped due to The investigators decided not to proceed with this study)
Effects of Intravenous Iron Supplementation on Exercise Capacity During Sustained Alveolar Hypoxia in Healthy Humans.[NCT01265108]	Phase 1	12 participants (Actual)	Interventional	2010-11-30	Completed
Can Prebiotics Support the Treatment of Mild Iron Deficiency by Iron Supplementation[NCT03850652]		20 participants (Anticipated)	Interventional	2019-03-06	Recruiting
Efficacy of Iron Fortified Ultra Rice Compared to Supplemental Iron Drops in Infants and Young Children[NCT00839761]		175 participants (Actual)	Interventional	2006-12-31	Completed
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-Dialysis Dependent Chronic Kidney Disease (PK-CKD-03)[NCT01213992]	Phase 1	16 participants (Actual)	Interventional	2012-03-31	Completed
Efficacy and Safety of Erythropoietin And/Or Intravenous Iron Sucrose For Treatment of Anemia In Hip and Knee Arthroplasty: A Single-center Retrospective Study[NCT03917394]		780 participants (Anticipated)	Observational	2019-04-24	Recruiting
Trial of Pre-Pregnancy Supplements[NCT01183572]		802 participants (Actual)	Interventional	2010-08-31	Completed
Multicenter, Open-label Active-controlled Randomized Study of Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia) Compared With Maltofer® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewab[NCT03993288]	Phase 3	267 participants (Actual)	Interventional	2019-06-27	Completed
Assessment of Iron Absorption and Requirements During Pregnancy and Lactation in Kenyan Women[NCT05973552]		250 participants (Anticipated)	Observational	2023-07-31	Recruiting
Verification of Correlation Between Genetic Testing of Nutritional Metabolism and Clinical Biochemical Indicators[NCT03651934]		600 participants (Anticipated)	Interventional	2018-10-01	Not yet recruiting
Iron Status, Maternal Depressive Symptoms, and Mother-child Interactions[NCT03944733]		0 participants (Actual)	Interventional	2019-12-01	Withdrawn(stopped due to The study was never started as a result of change of personnel and funding)
A Double-blind, Placebo Controlled Study to Assess Efficacy of 5-Aminolevulinic Acid in Subjects With Iron Deficiency Anemia[NCT01380548]		135 participants (Anticipated)	Interventional	2011-06-30	Completed
Iron Deficiency Anemia and Infant Behavior: Preventive Trial[NCT01166451]		835 participants (Actual)	Interventional	1991-09-30	Completed
Effectiveness of Adaptation of the Dose of Iron Supplementation in Pregnancy on Maternal-child Health. Randomized Clinical Trial (ECLIPSES)[NCT03196882]	Phase 4	704 participants (Actual)	Interventional	2013-07-10	Completed
Use of Cast Iron Pots to Improve Maternal Anemia[NCT02341300]		34 participants (Actual)	Interventional	2020-07-15	Terminated(stopped due to Original investigator has left the institution.)
A Cluster-randomized, Non-inferiority Open-label Trial of the Impact of Supplementation Regimen on Consumption of Prenatal Calcium and Iron/Folic Acid Supplements and Adherence to Related Recommendations[NCT02238704]		1,032 participants (Actual)	Interventional	2014-09-30	Completed
A Randomized Trial to Determine if RBCs From Donors With Iron Deficient Erythropoiesis Have Decreased Post-transfusion RBC Recovery and Whether Iron Repletion Improves Recovery[NCT02889133]		85 participants (Actual)	Interventional	2017-01-31	Active, not recruiting
A Randomized Controlled Pilot Study of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients With Functional Iron Deficiency, With and Without Oxandrolone[NCT02047552]	Phase 2	0 participants (Actual)	Interventional	2015-01-31	Withdrawn(stopped due to No Participants enrolled)
A Phase III, Randomised, Open-label, Comparative Safety and Efficacy Trial of Intravenous Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Dis[NCT02940860]	Phase 3	1,538 participants (Actual)	Interventional	2016-11-29	Completed
Fermented Iron-rich Supplement in Reducing Anemia[NCT02037724]	Phase 2	120 participants (Anticipated)	Interventional	2014-03-31	Not yet recruiting
Efektifitas Pemberian Zat Besi Dan Vitamin D Terhadap Status Besi Pada Anak Dengan Anemia Defisiensi Besi[NCT06148545]		57 participants (Actual)	Interventional	2023-03-30	Completed
A Study of Efficacy and Safety of Three Different Oral Iron-Containing Dietary Supplements in Correction of Hematological Indices and Replenishment of Depleted Iron Stores in Iron Deficient Adults With or Without Mild Microcytic Anemia[NCT05185024]		152 participants (Actual)	Interventional	2022-01-19	Active, not recruiting
Intravenous Ferric Carboxymaltose Versus Oral Ferrous Sulfate Replacement in Anaemia Due to Acute Nonvariceal Gastrointestinal Bleeding (FIERCE): Protocol of a Multicentre Randomised Controlled Trial[NCT05060731]	Phase 4	570 participants (Anticipated)	Interventional	2024-09-01	Not yet recruiting
A Randomized Open-label Trial Cross-over Trial of Iron Isomaltoside 1000 (Monofer®) Compared With Iron Sucrose (Venofer®) in Peritoneal Dialysis Patients[NCT03610230]		16 participants (Actual)	Interventional	2019-02-01	Terminated(stopped due to Difficult patient recruitment due to COVID-19 epidemic)
Obesity, Iron Regulation and Colorectal Cancer Risk[NCT03548948]		17 participants (Actual)	Interventional	2015-07-15	Completed
A Repeat Dose, Open Label, Two Period, Randomized, Cross Over Study to Compare the Effect of Daprodustat to Recombinant, Human Erythropoietin (rhEPO) on Oral Iron Absorption in Adult Participants With Anemia Associated With Chronic Kidney Disease Who Are [NCT03457701]	Phase 2	15 participants (Actual)	Interventional	2019-07-30	Completed
The Effect of Zinc on Iron Bioavailability From Fortified Extruded Rice Fortified With Ferric Pyrophosphate[NCT02255942]		20 participants (Actual)	Interventional	2015-04-30	Completed
Outcome of Oral Lactoferrin in Comparison to Amino Acid Chelated Iron and Ferrous Sulphate Supplementation During Pregnancy: A Randomized Control Trial[NCT03542825]	Phase 4	300 participants (Actual)	Interventional	2018-01-01	Completed
[NCT01864161]	Phase 4	100 participants (Actual)	Interventional	2011-10-31	Completed
The Effect of Prebiotics on Iron Absorption in Women With Low Iron Stores: Determination of a Dose-dependent Effect of Galacto-oligosaccharides on Iron Absorption, With and Without Addition of Ascorbic Acid[NCT03762148]		46 participants (Actual)	Interventional	2019-04-01	Completed
Treatment of Iron Defieciency Anemia[NCT02957643]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2016-11-30	Completed
Intravenous Iron Isomaltoside Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy: A Randomized Comparative Trial[NCT05251493]	Phase 3	280 participants (Anticipated)	Interventional	2022-06-06	Recruiting
A Randomized Control Trial of the Lucky Iron Fish to Improve Hemoglobin Concentration in Women in Preah Vihear, Cambodia[NCT02341586]		340 participants (Actual)	Interventional	2015-04-30	Completed
EXPLorative Data Collection for Patient chAracterIzation, treatmeNt Pathways and Outcomes of IRON Preparations[NCT03382275]		51 participants (Actual)	Observational [Patient Registry]	2018-01-16	Completed
16 Weeks' Dietary Supplementation With Iron and Iron + Vitamin C on Cerebral Blood Flow and Energy Expenditure in Women of Reproductive Age[NCT04477018]		78 participants (Actual)	Interventional	2017-11-11	Completed
Evaluation of the Efficacy of Different Strategies to Treat Anemia in Mexican Children: A Randomized Clinical Trial[NCT00822380]		680 participants (Actual)	Interventional	2003-03-31	Completed
The Optimization of Bioavailability From Iron Supplements: Examinations of Different Supplementation Regimens Including Hepcidin Profiles[NCT02175888]		20 participants (Actual)	Interventional	2015-10-31	Completed
Scaling-up High-impact Micronutrient Supplementation Interventions to Improve Adolescents' Nutrition and Health in Burkina Faso[NCT04657640]	Phase 3	2,100 participants (Anticipated)	Interventional	2020-12-11	Active, not recruiting
Daily vs Alternate Day Iron Supplementation for Pregnant Women With Iron Deficiency Anemia: A Randomized Controlled[NCT03562143]		88 participants (Actual)	Interventional	2018-08-31	Completed
Efficacy Evaluation of 16 Weeks' Dietary Supplementation With Iron Bis-glycinate Plus Vitamin C on Cognitive Function, Subjective Mood, Fatigue, Health and Well-being in Non-anaemic Iron Deficient and Iron Sufficient Women of Reproductive Age[NCT04469010]		151 participants (Actual)	Interventional	2017-06-02	Completed
Effects Intravenous Iron and Oral Iron Therapy on Erythropoietin Dose in Maintenance Hemodialysis Patients: An Open-label, Randomized, Controlled Study[NCT04464850]	Phase 3	124 participants (Anticipated)	Interventional	2020-07-29	Recruiting
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)(PK-CIA-04)[NCT01213979]	Phase 1	16 participants (Actual)	Interventional	2012-02-29	Completed
Iron Absorption From Iron-fortified Infant Formula and Iron Drops in Infants (MJAU-studien)[NCT01216709]		72 participants (Actual)	Interventional	2010-10-31	Completed
Iron Bioavailability From Fortified Cereal in Malawian Infants[NCT03754543]		30 participants (Actual)	Interventional	2019-01-31	Completed
Randomized Open Comparative Trial of Oral Sucrosomial Iron (SiderAl Forte®) and Oral Iron Sulphate (Duroferon®) to Blood Donors.[NCT05678647]		120 participants (Anticipated)	Interventional	2023-01-31	Recruiting
A Dose Ranging Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) Versus Control in Subjects With ESRD Receiving Chronic Hemodialysis.[NCT00548249]	Phase 2	131 participants (Actual)	Interventional	2007-08-31	Completed
The Effects of a Dietary Iron Program on Iron Status and Cognitive Function Amoung School Children in Phatthalung Province, Southern Thailand[NCT05878379]		34 participants (Actual)	Interventional	2018-05-02	Completed
The Effectiveness of Single Versus Double Daily Dose of Oral Iron on the Prevention of Iron Deficiency Anemia in Obese Pregnant Women[NCT04101461]		230 participants (Actual)	Interventional	2019-10-01	Completed
Treatment of Anemia With Intravenous Iron in Patients Listed for Orthotopic Liver Transplantation[NCT04475887]	Phase 4	60 participants (Anticipated)	Interventional	2020-07-23	Recruiting
Effects of Early Parenteral Iron Combined Erythropoietin in Preterm Infants[NCT02060851]	Phase 4	96 participants (Actual)	Interventional	2014-02-28	Completed
Doubling the Iron Dose VS Single Dose Iron Supplementation to Prevent Iron Deficiency Anemia (IDA) in Twin Pregnant Women: A Randomized Controlled Trial[NCT03836703]	Phase 4	450 participants (Actual)	Interventional	2019-02-01	Completed
Effect of Infant Formula With Bovine Lactoferrin and Low Iron Concentration on Infant Health and Immune Function[NCT02103205]		252 participants (Actual)	Interventional	2014-06-30	Active, not recruiting
Preoperative, Single-dose Intravenous Iron Formulation to Reduce Post-surgical Complications in Patients Undergoing Major Abdominal Surgery: a Pilot Randomised Control Trial (PIRCAS Trial - Pilot)[NCT03295851]	Phase 4	60 participants (Anticipated)	Interventional	2017-11-22	Recruiting
Comparison of Home Fortification With Two Iron Formulations in Kenyan Children Protected Against Malaria by Artemisinin-based Combination Therapy: a Placebo-controlled Non-inferiority Trial[NCT02073149]	Phase 2/Phase 3	338 participants (Actual)	Interventional	2014-06-30	Completed
A Randomized, Double-blind, Parallel, Three-arms, Placebo-controlled, Safety and Efficacy Study of Botanical Extract Standardized for Iron + Vitamin C and Botanical Extract Standardized for Iron in Adult Human Subjects With Anemia or Iron-deficiency Anemi[NCT06096103]		96 participants (Anticipated)	Interventional	2023-11-15	Not yet recruiting
The Optimization of Bioavailability From Iron Supplements: Examinations of Different Supplementation Regimens Including Hepcidin Profiles[NCT02177851]		20 participants (Actual)	Interventional	2015-06-30	Completed
Phase II Multiple-Dose Treatment of New Onset Type 1 Diabetes Mellitus With Anti-CD3 mAb[NCT00129259]	Phase 2	83 participants (Actual)	Interventional	2005-09-30	Completed
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas[NCT03897673]		600 participants (Anticipated)	Interventional	2019-09-01	Enrolling by invitation
Do Oral Contraceptives Protect Against Anterior Cruciate Ligament Injuries in Female Athletes[NCT04899778]	Phase 4	100 participants (Anticipated)	Interventional	2021-09-29	Recruiting
Physiology Study Investigating the Effects of Supplementation and Depletion of Iron on Hypoxia-related Pulmonary Hypertension[NCT00952302]		33 participants (Actual)	Interventional	2008-10-31	Completed
A Randomized, Open-Label, Single-Dose, Parallel-Design, Bioequivalence Study of Hospira Iron Sucrose Injection Compared to Venofer® Injection USP in Healthy Subjects.[NCT00719459]	Phase 1	60 participants (Actual)	Interventional	2008-06-30	Completed
Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] Dose Escalation Study for the Treatment of Advanced Solid Tumors: Phase 1 Clinical Trial[NCT06048367]	Phase 1	24 participants (Anticipated)	Interventional	2022-10-14	Recruiting
A Prospective, Randomized, Multi-centered Trial to Compare the Efficacy and Safety of Intravenous Iron Sucrose (Venoferrum®) With Oral Iron Acetyl-transferrin Hydroglycerin (Bolgre®) in Pregnant Women With Iron Deficiency Anemia[NCT00802139]	Phase 4	58 participants (Actual)	Interventional	2008-02-29	Completed
Rationale and Design of Ferric Polymaltose Hydroxide and Iron Sucrose Evaluation on Performance and Oxydative Stress in Patient With Iron deficIency and Stable Heart Failure Study[NCT04225728]	Phase 4	45 participants (Actual)	Interventional	2017-12-01	Completed
Efficacy and Safety of Parenteral Nutrition With Iron Sucrose for Anemia in Preterm Infants: a Randomized, Double-blind Controlled Study[NCT02743572]		129 participants (Actual)	Interventional	2015-09-30	Completed
Maternal Iron Absorption and Utilization and Iron Transfer to the Fetus During Pregnancy in Normal Weight and Overweight/Obese Women and the Effects on Infant Iron Status[NCT02747316]		83 participants (Actual)	Interventional	2016-02-29	Completed
The Iron Content of Ferritin in Serum and Urine of Children With High Serum Ferritin Levels[NCT03777904]		11 participants (Actual)	Observational	2019-02-21	Terminated(stopped due to Analysis of first 11 subjects resulted in values that were too varied to make the study feasible.)
Randomized Trial of Higher-dose Iron (60 mg, 45 mg) Compared to Low-dose Iron (30 mg) in Multiple Micronutrient Supplements in Pregnancy on Moderate and Severe Maternal Anemia[NCT06079918]	Phase 3	6,381 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
Testing Iron Absorption From a New Micronutrient Powder Containing Galacto-oligosaccharides (GOS) for Fortification of Infant Foods in Sub-Saharan Africa[NCT02666417]		64 participants (Actual)	Interventional	2016-01-31	Completed
Acceptability and Feasibility of Micronutrient Powders Versus Iron Syrup for Anemia Prevention in Young Children[NCT02610881]		110 participants (Actual)	Interventional	2015-12-31	Completed
Phase IV Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency[NCT02213653]	Phase 4	24 participants (Actual)	Interventional	2013-04-30	Terminated
Identification of Sentinel Lymph Nodes by Ultrasound Utilizing Iron Tracer Injection and Preoperative Biopsy in Women With Breast Cancer[NCT02610920]	Early Phase 1	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Unable to enroll subjects)
Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion and Improving Outcomes in Patients Undergoing CABG. A Prospective Randomized Trial[NCT04061655]	Early Phase 1	80 participants (Actual)	Interventional	2019-09-20	Completed
Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors : a Randomized Controlled Trial[NCT00689793]	Phase 4	154 participants (Actual)	Interventional	2008-11-30	Completed
Non-invasive Optical Detection of Iron Deficiency in Children- Evaluation of a Fiber Optic Tissue Fluorescence Measurement to Determine the Erythrocyte Zinc Protoporphyrin-IX/Heme Ratio[NCT02701309]		100 participants (Actual)	Observational	2016-04-30	Completed
Effects of a Commercially-available, Low-dose Iron Supplement (BloodBuilder®/Iron Response®) on Markers of Iron Status Among Premenopausal and Non-anemic, Iron-deficient Women[NCT02683369]	Phase 2/Phase 3	23 participants (Actual)	Interventional	2016-02-29	Completed
An Open, Randomized, Controlled, Parallel Group, Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate Together With a Randomized Placebo Controlled Double Blind Fermagate Comparison in Hemodialysis Patients With Hype[NCT00841126]	Phase 3	657 participants (Anticipated)	Interventional	2009-07-31	Terminated
Combination With Intravenous Iron Supplementation or Doubling Erythropoietin Dose for Patients With Chemotherapy-induced Anaemia Inadequately Responsive to Initial Erythropoietin Treatment Alone[NCT02731378]	Phase 4	603 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Iron Supplementation to Reduce Preschoolers Anemia: Comparison Between Intermittent and Cyclic Procedure[NCT00992823]		99 participants (Actual)	Interventional	2006-03-31	Completed
Antenatal Multiple Micronutrient Supplementation to Improve Infant Survival and Health in Bangladesh[NCT00860470]	Phase 3	44,567 participants (Actual)	Interventional	2008-01-31	Completed
Individually Randomized Crossover Trial of Multiple Micronutrient Supplementation (MMS) Iron Doseages During Pregnancy in Tanzania[NCT06069869]	Phase 3	156 participants (Anticipated)	Interventional	2025-09-30	Not yet recruiting
Lactoferrin With Iron Versus Iron Alone in Treatment of Anemia In Chronic Liver Disease[NCT04335058]		130 participants (Anticipated)	Interventional	2020-01-01	Recruiting
Efficacy of Intravenous Ferric Carboxymaltose in the Improvement of Anemia in Patients With Postoperative Knee Prosthesis[NCT01913808]	Phase 4	122 participants (Actual)	Interventional	2011-01-31	Completed
Individually Randomized Trial of Higher-dose Iron (60 mg, 45 mg) Compared to Low-dose Iron (30 mg) in Multiple Micronutrient Supplements in Pregnancy on Moderate and Severe Maternal Anemia- MMS Versus IFA Crossover Trial[NCT06069856]	Phase 3	130 participants (Anticipated)	Interventional	2025-09-30	Not yet recruiting
Study of the Effects of Iron Supplementation on High Altitude Pulmonary Hypertension.[NCT00960921]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to Study never started.)
A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency.[NCT01067547]	Phase 4	130 participants (Actual)	Interventional	2010-03-31	Completed
Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation[NCT01047098]		114 participants (Actual)	Interventional	2008-10-31	Completed
A Clinical Pharmacological Study to Evaluate the Effects of Iron Supplements on the Pharmacokinetics of MT-6548 in Healthy Male Volunteers[NCT03645863]	Phase 3	61 participants (Actual)	Interventional	2018-08-27	Completed
Evaluation of the Effect of Body Weight and Composition on Iron Absorption and Blood Volume[NCT01884506]		64 participants (Actual)	Interventional	2013-06-30	Completed
Phase III Randomized Double Blind Placebo-Controlled Study To Assess The Effects Of FeraMax When Administered Orally Once A Day On Postoperative Fatigue Levels In Patients Following Elective Coronary Artery Bypass Graft Surgery (CABG)[NCT01912261]	Phase 3	121 participants (Actual)	Interventional	2014-12-16	Terminated(stopped due to The study was stopped due to time constraints and resources)
Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes[NCT00470158]	Phase 4	1,000 participants (Actual)	Interventional	2007-05-31	Completed
Iron Isomaltoside 1000 in Patients With Iron Deficiency or Iron Deficiency Anemia: a Multicentric, Prospective, Longitudinal, Observational Study in Switzerland.[NCT04318405]		327 participants (Actual)	Observational	2020-07-10	Completed
Evaluation of the Effects of an Exogenous Phytase on Iron Absorption From Lipid Nutrient Supplements Added to Complementary Foods[NCT01991626]		47 participants (Actual)	Interventional	2013-09-30	Completed
Comparison Between Aminoacid Chelated Iron and Iron Salt in Treatment of Iron Deficiency Anemia With Pregnancy[NCT02005588]	Early Phase 1	150 participants (Actual)	Interventional	2013-12-31	Completed
An Open-label, Randomised, Active Controlled Multi-center Phase II Dose Finding Study to Evaluate the Ability of PA21 to Lower Serum Phosphate Levels and the Tolerability in Patients With Chronic Kidney Disease on Maintenance Hemodialysis[NCT00824460]	Phase 2	154 participants (Actual)	Interventional	2008-12-31	Completed
Comparative Cross-over Study to Evaluate the Rate and the Extent of Iron Absorption of a New Iron Supplement (With Orodispersible Formulation) vs an Iron Supplement in Capsules, After Administration of a Single Dose in Healthy Volunteers[NCT05660200]		9 participants (Actual)	Interventional	2022-11-25	Completed
Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia.[NCT00199277]	Phase 4	150 participants	Interventional		Not yet recruiting
[NCT02858505]	Phase 2	120 participants (Actual)	Interventional	2015-08-31	Completed
Evaluation of the Effect of Lactoferrin Versus Intravenous Iron Sucrose in Treatment of Iron Deficiency Anemia During Pregnancy[NCT05921968]	Phase 4	100 participants (Anticipated)	Interventional	2023-07-30	Not yet recruiting
A Randomized Double-Blind Safety Comparison of Intravenous Iron Dextran Versus Iron Sucrose in an Adult Non-Hemodialysis Outpatient Population: A Pilot Study[NCT00593619]	Phase 4	200 participants (Anticipated)	Interventional	2008-01-31	Suspended(stopped due to Interim Analysis and review by Data Safety Monitoring Board)
A Randomized, Open-Label, Wait-list Control Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia and a Serum Ferritin Between 20 and 200 ng/mL[NCT01309659]	Phase 2	19 participants (Actual)	Interventional	2011-05-31	Terminated(stopped due to Lack of Enrollment)
Effects of Intermittent Iron and Vitamin A Supplementation on Nutritional Status and Development of Schoolchildren in Arba Minch Zuria District, Ethiopia.[NCT04137354]		504 participants (Actual)	Interventional	2020-11-02	Completed
Teff (Eragrostis Tef) as a Functional Food for the Prevention of Pregnancy Iron-deficiency Anemia[NCT01055431]	Phase 1	55 participants (Actual)	Interventional	2009-10-31	Completed
Comparison of Iron Absorption From Extruded FePP-fortified Rice Containing Different Zinc Compounds, Citric Acid/Trisodium Citrate and Sodium EDTA[NCT02714075]		30 participants (Actual)	Interventional	2016-04-30	Completed
Randomized Trial Comparing Iron Supplementation Versus Routine Iron Intake in Very Low Birth Weight Infants[NCT01125163]		150 participants (Actual)	Interventional	2010-05-31	Completed
Randomized Controlled Trial of Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis[NCT05225545]	Phase 3	30 participants (Anticipated)	Interventional	2019-11-04	Recruiting
Timing, Duration and Severity of Infant Iron Deficiency: Developmental Impacts[NCT00613717]		2,371 participants (Actual)	Interventional	2009-11-30	Completed
The Role of Sub-clinical Inflammation on the Iron Status of Myanmar Anaemic Adolescent Schoolgirls During Iron and Vitamin A Supplementation[NCT01198574]	Phase 3	402 participants (Actual)	Interventional	2010-07-31	Completed
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia[NCT00236977]	Phase 3	182 participants (Actual)	Interventional	2003-08-31	Completed
Iron-Deficiency Anemia in Infants: Comparative Study of Two Weekly Supplement Programs[NCT00655408]		130 participants (Actual)	Interventional	2003-04-30	Completed
Monthly Itraconazole Versus Classic Homeopathy for the Treatment of Recurrent Vulvovaginal Candidiasis: a Randomised Trial[NCT00895453]		144 participants (Actual)	Interventional	2000-05-31	Completed
Impact of Vitamin B12 Supplementation With Iron and Folic Acid on Adolescent Girls[NCT01490944]	Phase 2	360 participants (Anticipated)	Interventional	2012-01-31	Recruiting
Randomized Trial Comparing Intravenous Iron Carboxymaltose, Intravenous Iron Isomaltoside and Oral Iron Sulphate for Postpartum Anemia[NCT03957057]	Phase 3	300 participants (Actual)	Interventional	2020-09-10	Completed
Swiss Functional Iron Deficiency Study[NCT00495781]		77 participants (Actual)	Interventional	2004-10-31	Completed
Assessment of the Bioavailability of Iron in Iron Fortified Bouillon Cubes in Healthy Nigerian Women[NCT02815449]		24 participants (Actual)	Interventional	2017-05-08	Completed
Iron Metabolism in Small Pre Term Newborns[NCT01443195]		50 participants (Anticipated)	Interventional	2011-10-31	Active, not recruiting
Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty: a Randomized Controlled Trial[NCT01857011]	Phase 3	56 participants (Actual)	Interventional	2014-04-30	Completed
A Pilot Study Comparing Tolerance of Oral Heme Iron Polypeptide With Oral Ionic Iron[NCT01865175]	Phase 4	0 participants (Actual)	Interventional	2016-01-31	Withdrawn(stopped due to Institution required IND, although FDA did not, so institution did not allow enrollment)
A Phase 2, Randomized, Open-Label, Dose Titration, Safety and Efficacy Study of FG-4592 for the Correction of Anemia in Newly Initiated Dialysis Patients Not on Erythropoiesis-Stimulating Agent Treatment[NCT01414075]	Phase 2	60 participants (Actual)	Interventional	2011-07-21	Completed
Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial[NCT03830034]	Phase 4	150 participants (Anticipated)	Interventional	2019-02-02	Recruiting
Evaluation of Iron Absorption From Ferric Ammonium Phosphate and Ferric Pyrophosphate From an Instant Milk Drink in Young Children[NCT05642689]		40 participants (Actual)	Interventional	2009-11-30	Completed
Sucrosomial Iron Supplementation in Anaemic Patients With Celiac Disease Not Tolerating Oral Ferrous Sulfate[NCT02916654]		20 participants (Anticipated)	Interventional	2015-04-30	Recruiting
HiFIT Study: Interest of Intravenous Iron and Tranexamic Acid to Reduce Transfusion in Hip Fracture Patients[NCT02972294]	Phase 3	419 participants (Actual)	Interventional	2017-03-31	Terminated(stopped due to 1year inclusion hold due to PV new fact (Monofer hold for risk revaluation) DSMB Interim analysis : 1treatment with important transfusion risk reduction/inclusions issues (COVID)/sites change of practice if study continue=>stop inclusions)
Effects of Oral Iron Supplementation Before vs. at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women[NCT05919472]		180 participants (Anticipated)	Interventional	2023-07-01	Recruiting
Impact of Zinc Supplementation on Mortality and Hospitalizations in Children Aged 1 Months to 23 Months[NCT00269542]		94,359 participants (Actual)	Interventional	2002-02-28	Completed
Meals to Improve Absorption of Iron Supplements and Iron Status in Iron Deficient Women of Reproductive Age: a Randomized, Controlled Trial[NCT04793906]		80 participants (Anticipated)	Interventional	2021-05-10	Recruiting
A Single-center, Double-blinded, Randomized, 12 Week, Superiority Study in Infants and Young Children to Compare the Efficacy of NovaFerrum® Versus Ferrous Sulfate in the Treatment of Nutritional Iron Deficiency Anemia.[NCT01904864]	Phase 4	80 participants (Actual)	Interventional	2013-07-31	Completed
Assessment of Complementary Feeding of Canadian Infants[NCT01790542]		87 participants (Actual)	Interventional	2012-12-31	Completed
Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia[NCT00482716]	Phase 3	80 participants (Anticipated)	Interventional	2007-01-31	Active, not recruiting
Double-blind Comparator of Efficacy of Oral (Ferrous Sulfate) vs. Intravenous Iron (Ferumoxytol) for Treatment of the Restless Legs Syndrome (RLS) Occurring With Iron Deficient Anemia (IDA)[NCT02499354]	Phase 2	100 participants (Actual)	Interventional	2014-08-31	Completed
Evaluation of the Validity of a Novel Isotope Dilution Method to Assess the Iron Status and Its Changes in Swiss Women[NCT02979132]		60 participants (Anticipated)	Interventional	2017-09-01	Active, not recruiting
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in [NCT01324128]	Phase 3	1,059 participants (Actual)	Interventional	2011-03-31	Completed
Iron Sucrose Combined With rHuEPO and Ascorbic Acid on Perioperative Allogeneic Red Blood Cell Infusion in Patients Undergoing Elective Major Cardiac Surgery[NCT05353348]		370 participants (Anticipated)	Interventional	2023-02-15	Recruiting
Effects of a Dietary Approach to Iron Deficiency in Premenopausal Women Affected by Celiac Disease[NCT02949765]		35 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Safe and Effective Delivery of Supplemental Iron to Healthy Volunteers[NCT03212677]		224 participants (Anticipated)	Interventional	2017-05-17	Recruiting
Study to Measure the Absorption of Iron From Ferrous Gluconate Incorporated Into Alginate Beads.[NCT01528644]		16 participants (Actual)	Interventional	2012-02-29	Completed
The Value of Iron Treatment for Postoperative Obstetric Patients With Anemia: a Randomized Double Blind Controlled Trial[NCT01975272]	Phase 4	27 participants (Actual)	Interventional	2015-03-02	Terminated(stopped due to Disapointing randomization rate)
A Randomized, Controlled, Double Blinded Clinical Trial of Intravenous Iron Sucrose in Adolescents With Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)[NCT01978535]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2014-12-17	Terminated(stopped due to Difficulty in recruiting subjects.)
Testing Iron Absorption From a New Micronutrient Powder Containing Galacto-oligosaccharides (GOS) for Fortification of Infant Foods in Sub-Saharan Africa[NCT02989311]		23 participants (Actual)	Interventional	2016-08-31	Completed
Monocentric, Prospective, Randomized Study to Evaluate the Efficacy of a New Iron Supplement With Orodispersible Formulation vs an Iron Supplement in Capsules in Subjects With Mild Anemia[NCT05989984]		60 participants (Anticipated)	Interventional	2023-08-04	Recruiting
A Phase III, Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of PGL4001 (Ulipristal) Versus Placebo for Pre-Operative Treatment of Symptomatic Uterine Myomas[NCT00755755]	Phase 3	241 participants (Actual)	Interventional	2008-10-31	Completed
ANEMEX UK Trial: Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial[NCT03214627]		88 participants (Actual)	Interventional	2018-12-10	Terminated(stopped due to Standard clinical practice at site caused unforeseen issues for the use of the ACM)
Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Moderate to Severe Iron Deficient Anemia of Pregnancy in Women Intolerant of or Responsive to Oral Iron.[NCT02038023]	Phase 2	74 participants (Actual)	Interventional	2013-07-31	Completed
Prevention of Iron Deficiency Anemia Post-delivery (PRIORITY Trial): A Randomized Controlled Trial of the Global Network for Women's and Children's Health Research[NCT05590260]	Phase 3	4,800 participants (Anticipated)	Interventional	2023-05-30	Recruiting
Comparison of the Safety and Efficacy of Three Iron Sucrose Maintenance Regimens in Pediatric Chronic Kidney Disease (CKD) Patients[NCT00239642]	Phase 4	141 participants (Actual)	Interventional	2005-07-31	Completed
Comparison of Iron Absorption From Regular-iron, Iron Biofortified, and Post-harvest Iron-fortified Pearl Millet Using Multiple Meals in Young Women[NCT01634932]		22 participants (Actual)	Interventional	2012-07-31	Completed
[NCT01733979]		80 participants (Actual)	Interventional	2012-02-07	Completed
Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria[NCT01754701]		100 participants (Actual)	Interventional	2013-06-30	Completed
Chelated Oral Iron Versus Intravenous Iron Sucrose for Treatment of Iron Deficiency Anemia Late in Pregnancy ( Randomized Controlled Trial )[NCT05151679]		0 participants	Expanded Access		Available
Is Iron Deficiency the Cause of Anemia Among Women of Reproductive Age in Cambodia? A 2 x 2 Factorial Double Blind Randomized Controlled Trial of Oral Iron and Multiple Micronutrient Supplementation[NCT02481375]		809 participants (Actual)	Interventional	2015-07-31	Completed
Defining the Functional and Metabolic Role of Iron in Aerobic Training and Physical Performance[NCT03002090]		109 participants (Actual)	Interventional	2014-08-31	Completed
Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease[NCT02151643]	Phase 2	153 participants (Actual)	Interventional	2014-05-07	Completed
A Randomised Phase II Trial of Iron Isomaltide Versus Oral Iron Supplement for Radiotherapy or Chemotherapy Associated Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma[NCT05913414]	Phase 2	120 participants (Anticipated)	Interventional	2023-05-05	Recruiting
Role of Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in the Pathophysiology of Ischemic Stroke in Human and Albino Rats[NCT05748587]		48 participants (Anticipated)	Observational	2023-04-01	Recruiting
A Comparison Between Intravenous Iron Sucrose to Its Combination With Oral Iron Supplements for the Treatment of Postpartum Anemia[NCT02458625]		158 participants (Actual)	Interventional	2016-04-30	Completed
Zinc, Iron and Vitamin A Supplementation for Infant Growth and Development, and the Contributing Role of Psychosocial Care[NCT02319499]	Phase 3	800 participants (Actual)	Interventional	1998-08-31	Completed
Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic Congenital Heart Disease - A Prospective Randomized Control Trial[NCT02564796]	Phase 2	4 participants (Actual)	Interventional	2016-11-30	Terminated(stopped due to COVID)
Nutri-CAP: Nutrition for Children, Adolescent Girls, and Pregnant Women in Slums of Dhaka City[NCT05311436]		3,260 participants (Anticipated)	Interventional	2022-07-01	Recruiting
Efficacy and Safety of Perioperative Iron Supplementation for Postoperative Rehabilitation of Geriatric Hip Fractures: a Multicenter, Randomized, Controlled Trial.[NCT05489952]	Phase 4	444 participants (Anticipated)	Interventional	2022-09-15	Recruiting
A Randomised, Double-blinded, Parallel Group Study to Demonstrate the Adherence and Efficacy of Different Doses of Iron Supplement in Subjects With or At-risk of Iron Deficiency With a History of Intolerance to Oral Iron[NCT04778072]		60 participants (Anticipated)	Interventional	2018-10-08	Active, not recruiting
Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease[NCT05456932]	Phase 4	90 participants (Anticipated)	Interventional	2022-08-19	Recruiting
Prospective Study of Iron Deficiency Anemia in Twin Pregnancy[NCT04975074]	Phase 4	1,000 participants (Anticipated)	Interventional	2021-07-15	Not yet recruiting
Randomized, Double-blind, Community-based Efficacy Trial of Various Doses of Zinc in Micronutrient Powders or Tablets in Young, Bangladeshi Children[NCT03406793]		2,886 participants (Actual)	Interventional	2018-02-20	Completed
Interactions of Lead Intoxication and Iron Deficiency in Morocco: The Effects of Iron Fortification With and Without NaEDTA on Lead Burden, Iron Status and Cognition in Children[NCT01573013]		457 participants (Actual)	Interventional	2011-09-30	Completed
Trial of Darbepoetin Plus Slow-release Intravenous Iron to Decrease Transfusions and Improve Iron Status and Neurodevelopment in Preterm Infants[NCT05340465]	Phase 2	120 participants (Anticipated)	Interventional	2022-11-27	Recruiting
A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemother[NCT01145638]	Phase 3	350 participants (Actual)	Interventional	2010-10-31	Completed
The Effects of Intravenous Iron Therapy for Anemia Correction in Patients With Severe Chronic Heart Failure and Concomitant Moderate Chronic Kidney Disease[NCT00384657]	Phase 3	0 participants (Actual)	Interventional	2008-01-31	Withdrawn(stopped due to Lack of cooperation among centers, Financial reasons)
FLIPS: Ferfer Liposomal Iron Performance Study[NCT03112187]	Phase 4	400 participants (Actual)	Interventional	2017-08-01	Completed
A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly (PROVIDE[NCT02130063]	Phase 3	511 participants (Actual)	Interventional	2014-05-31	Completed
Iron Bioavailability From Fortified Food in Healthy Women[NCT02993835]		23 participants (Actual)	Interventional	2016-12-31	Completed
Heme Iron Polypeptide for the Treatment of Iron Deficiency Anemia in Pre-Dialysis Patients: A Pilot Randomized Controlled Study[NCT00318812]	Phase 2/Phase 3	55 participants (Actual)	Interventional	2007-05-31	Completed
Iron Sucrose In The Treatment of Restless Legs Syndrome (RLS): The Safety of Three Dose Regimens as Evaluated by Clinical Assessments[NCT00895232]	Phase 2	21 participants (Actual)	Interventional	2003-11-30	Completed
Enteral Iron Supplementation and Intestinal Health in Preterm Infants[NCT04497012]	Phase 4	183 participants (Anticipated)	Interventional	2020-11-17	Recruiting
Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia (DEODO): a Multi-centered, Pilot Randomized Controlled Trial[NCT03725384]	Phase 3	52 participants (Actual)	Interventional	2019-01-04	Completed
Effectiveness of Quadruple Fortified Salt in Improving Hemoglobin Levels Among Anemic Women of Reproductive Age (18-49 Years) in Rural Low Resource Setting[NCT04404751]		174 participants (Actual)	Interventional	2019-08-23	Completed
Clinical Observation of The Gynecological Iron-Deficiency Anemia Treated With Buxue Yimu Pills[NCT03232554]	Phase 2	180 participants (Anticipated)	Interventional	2017-06-01	Recruiting
Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure[NCT02188784]	Phase 3	225 participants (Actual)	Interventional	2014-09-03	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Hemoglobin (Hb) From Baseline to Week 8

"Efficacy~Evaluate the effect on the hemoglobin (Hb) level following treatment with iron isomaltoside/ferric derisomaltose vs iron sucrose in subjects with iron deficiency anaemia (IDA) .~Response was defined as change from baseline in hemoglobin (Hb) to week 8, i.e. ability to increase Hb in subjects with IDA, when oral iron preparations were ineffective or could not be used or in whom the screening Hb measurement in Investigators' opinion were sufficiently low to require rapid repletion of iron stores." (NCT02940886)
Timeframe: Baseline to week 8

Intervention	g/dL (Least Squares Mean)
Iron Isomaltoside/Ferric Derisomaltose	2.49
Iron Sucrose	2.49

Composite Cardiovascular Adverse Events (AEs)

"Safety~Results show the composite cardiovascular adverse events (AEs), that started on or after the first dose of randomised treatment (i.e. treatment emergent) up to week 8.~The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC).~The potential cardiovascular AEs included the following:~Death due to any cause~Non-fatal myocardial infarction~Non-fatal stroke~Unstable angina requiring hospitalisation~Congestive heart failure requiring hospitalisation or medical intervention~Arrhythmias~Hypertension~Hypotension~Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs." (NCT02940886)
Timeframe: Baseline, week 1, 2, and 8

Intervention	Participants (Count of Participants)
Iron Isomaltoside/Ferric Derisomaltose	8
Iron Sucrose	6

Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8

"Efficacy~Results show the number of participants who achieved Hb concentration increase of ≥2 g/dL at any time from week 1 to week 8." (NCT02940886)
Timeframe: Week 1 to week 8

Intervention	Participants (Count of Participants)
Iron Isomaltoside/Ferric Derisomaltose	687
Iron Sucrose	340

Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8

"Efficacy~Hb concentration of >12 g/dL at any time from week 1 to week 8.~Results show the number of participants who achieved Hb concentration of >12 g/dL at any time from week 1 to week 8." (NCT02940886)
Timeframe: Week 1 to week 8

Intervention	Participants (Count of Participants)
Iron Isomaltoside/Ferric Derisomaltose	484
Iron Sucrose	225

Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions

"Safety~For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity reactions that were included in the analysis were those that started on or after the first dose of randomised treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: loss of consciousness, seizure, syncope, unresponsiveness.~The potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC).~Results show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions." (NCT02940886)
Timeframe: Baseline to week 8

Intervention	Participants (Count of Participants)
Iron Isomaltoside/Ferric Derisomaltose	3
Iron Sucrose	2

Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car

"Pharmacoeconomics~The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics.~The data for this endpoint show the responses at baseline for both treatment groups.~The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group)." (NCT02940886)
Timeframe: Baseline

Intervention	miles (Median)
Iron Isomaltoside/Ferric Derisomaltose	15.0
Iron Sucrose	15.0

S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8

"Efficacy~Proportion of subjects reaching the composite endpoint of s-ferritin concentration ≥100 ng/mL and TSAT of 20-50% at any time from week 1 to 8." (NCT02940886)
Timeframe: Week 1 to week 8

Intervention	Participants (Count of Participants)
Iron Isomaltoside/Ferric Derisomaltose	680
Iron Sucrose	164

S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8

"Safety~Results show the number of subjects who had s-phosphate <2 mg/dL at any time from baseline to week 1, 2, 4, or 8." (NCT02940886)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	Participants (Count of Participants)
Iron Isomaltoside/Ferric Derisomaltose	38
Iron Sucrose	11

Time to Change in Hb Concentration ≥2 g/dL

"Efficacy~Time to change in Hb concentration ≥2 g/dL. Subjects who achieved Hb concentration increase of ≥2 g/dL (from baseline to week 1, 2, 4, or 8).~For responders, time to Hb response was defined as the scheduled time from baseline until the visit where the first Hb response was measured." (NCT02940886)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	Days (Median)
Iron Isomaltoside/Ferric Derisomaltose	28
Iron Sucrose	28

Time to First Composite Cardiovascular Safety AE

"Safety~Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the CEAC, were considered for this endpoint.~Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit." (NCT02940886)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	Week (Median)
Iron Isomaltoside/Ferric Derisomaltose	NA
Iron Sucrose	NA

Change in Concentrations of Serum Iron (S-iron) From Baseline to Week 1, 2, 4, and 8

"Efficacy~Changes in the concentrations of serum iron (s-iron) from baseline to week 1, 2, 4, and 8." (NCT02940886)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	μg/dL (Mean)
	Week 1	Week 2	Week 4	Week 8
Iron Isomaltoside/Ferric Derisomaltose	63.2	38.8	31.2	24.2
Iron Sucrose	22.4	37.0	35.1	27.6

Change in Fatigue Symptoms From Baseline to Week 1, 2, and 8

"Efficacy~Change in fatigue symptoms from baseline to week 1, 2, and 8 was measured by the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale.~The Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale consisted of 13 items ranging from 0 (not at all) to 4 (very much), except items #7 and #8 which are reversed scored. The total score range is 0-52.~A score of less than 30 indicated severe fatigue, and the higher the score, the better outcome/quality of life (QoL). If more than 50% of the items for a subject at a given visit were missing, the total score was not calculated.~Total score was calculated as shown below:~Total score= Sum of individual scores x 13 / Number of items answered" (NCT02940886)
Timeframe: Baseline, week 1, 2, and 8

Intervention	score on a scale (Mean)
	Week 1	Week 2	Week 8
Iron Isomaltoside/Ferric Derisomaltose	7.98	10.74	14.08
Iron Sucrose	7.38	11.89	15.36

Change in Hb Concentration From Baseline to Week 1, 2, and 4

"Efficacy~Change in Hb concentration from baseline to week 1, 2, and 4." (NCT02940886)
Timeframe: Baseline, week 1, 2, and 4

Intervention	g/dL (Mean)
	Week 1	Week 2	Week 4
Iron Isomaltoside/Ferric Derisomaltose	0.70	1.49	2.15
Iron Sucrose	0.47	1.25	2.13

Change in S-ferritin Concentration From Baseline to Weeks 1, 2, 4, and 8

"Efficacy~Change in s-ferritin concentration from baseline to weeks 1, 2, 4, and 8." (NCT02940886)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	ng/mL (Mean)
	Week 1	Week 2	Week 4	Week 8
Iron Isomaltoside/Ferric Derisomaltose	373.5	211.8	98.0	49.0
Iron Sucrose	105.7	169.9	109.2	58.7

Change in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8

"Efficacy~Changes in transferrin saturation (TSAT) from baseline to week 1, 2, 4, and 8.~TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron." (NCT02940886)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	percentage of saturation (Mean)
	Week 1	Week 2	Week 4	Week 8
Iron Isomaltoside/Ferric Derisomaltose	16.68	12.33	11.63	9.01
Iron Sucrose	5.84	10.58	11.08	8.87

Hb Concentration Increase of ≥2 g/dL From Baseline to Week 1, 2, 4, and 8

"Efficacy~Results show responders to the treatment. A subject was considered a Hb responder to a certain week if an increase in Hb of at least 2 g/dL from baseline to the week in question was observed (week 1, 2, 4, and 8)." (NCT02940886)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	Participants (Count of Participants)
	Responder YES week 1	Responder YES week 2	Responder YES week 4	Responder YES week 8
Iron Isomaltoside/Ferric Derisomaltose	51	297	514	606
Iron Sucrose	12	94	250	309

Health Care Resource Use Questionnaire

"Pharmacoeconomics~Resources used by the health care staff (per administration), measured by the health care resource use questionnaire. The questionnaire assessed the time used by the health care staff during administration of the investigational product and the administration time (including the observational time). The health care participants included in the evaluation were: investigator, pharmacist, physician, study coordinator, study nurse.~The data for this endpoint show the responses at baseline for both treatment groups.~The frequency of drug administration between the treatment groups is different (i.e. up to a factor 5 more frequent in the iron sucrose treatment group)." (NCT02940886)
Timeframe: Baseline

Intervention	hours (Median)
	Time spent per site staff median	Time spent per subject median
Iron Isomaltoside/Ferric Derisomaltose	1.08	3.38
Iron Sucrose	1.00	3.00

Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Cost of Public Transport/Taxi And Parking

Intervention	US dollars ($) (Median)
	Cost of public transport/taxi	Cost of parking
Iron Isomaltoside/Ferric Derisomaltose	5.0	0.0
Iron Sucrose	5.0	0.0

Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Participants/Others Who Took Time Off Work to Attend Visits

Intervention	participants (Number)
	In employment, YES	Took time off work to attend, YES	Assistance by others to attend visit, YES	Others took time off work to attend, YES
Iron Isomaltoside/Ferric Derisomaltose	529	233	211	64
Iron Sucrose	258	113	111	32

Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Time Spent on Visit/Helping on Visit

Intervention	Hours (Median)
	Time spent on visit	Total time spent helping on visit
Iron Isomaltoside/Ferric Derisomaltose	2.0	2.0
Iron Sucrose	2.0	2.0

Change From Baseline in Blood Hemoglobin Level (g/L)

Changes in blood hemoglobin level (g/L) after 12-weeks of iron-deficiency anaemia treatment, a non-inferiority comparison, as compared with the baseline value (screening visit) between Ferrum Lek® and MALTOFER® groups (NCT03993288)
Timeframe: Baseline and Week 12

Intervention	g/L (Mean)
Ferrum Lek	18.33
MALTOFER	18.52

Number of Participants With Response to the Therapy

Response to the therapy is determined as an increase in hemoglobin level by 20 g/L and more after 12-weeks of treatment (NCT03993288)
Timeframe: Baseline and Week 12

Intervention	Participants (Count of Participants)
Ferrum Lek	59
MALTOFER	56

Change From Baseline in Ferritin

Change in average values of iron metabolism parameter ferritin during the treatment period (NCT03993288)
Timeframe: Baseline, Week 4, 8 and 12

Intervention	microgram/liter (Mean)
	Week 4	Week 8	Week 12
Ferrum Lek	3.48	4.9	7.62
MALTOFER	7.35	4.49	6.55

Change From Baseline in Percent Transferrin Saturation

Change in average values of iron metabolism parameter percent transferrin saturation during the treatment period (NCT03993288)
Timeframe: Baseline, Week 4, 8 and 12

Intervention	percent transferrin saturation (Mean)
	Week 4	Week 8	Week 12
Ferrum Lek	2.46	8.25	7.27
MALTOFER	4.44	5.47	8.03

Change From Baseline in Serum Iron

Change in average values of iron metabolism parameter serum iron during the treatment period (NCT03993288)
Timeframe: Baseline, Week 4, 8 and 12

Intervention	micromoles/liter (Mean)
	Week 4	Week 8	Week 12
Ferrum Lek	1.76	4.09	5.16
MALTOFER	3.42	4.34	6.12

Change From Baseline in Transferrin

Change in average values of iron metabolism parameter transferrin during the treatment period (NCT03993288)
Timeframe: Baseline, Week 4, 8 and 12

Intervention	g/L (Mean)
	Week 4	Week 8	Week 12
Ferrum Lek	-0.15	-0.22	-0.24
MALTOFER	-0.14	-0.22	-0.25

Change in Hemoglobin (Hb) From Baseline to Week 8

"Efficacy~Evaluate the effect of iron isomaltoside/ferric derisomaltose vs iron sucrose in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).~Response was defined as change from baseline in hemoglobin (Hb) to week 8, i.e. ability to increase Hb in subjects with NDD-CKD and IDA, when oral iron preparations were ineffective or could not be used, or in whom the Hb measurement at screening in Investigators' opinion were sufficiently low to require rapid repletion of iron stores." (NCT02940860)
Timeframe: Baseline to week 8

Intervention	g/dL (Least Squares Mean)
Iron Isomaltoside/Ferric Derisomaltose	1.22
Iron Sucrose	1.14

Composite Cardiovascular Adverse Events (AEs)

"Safety~Results show the composite cardiovascular AEs, that started on or after the first dose of randomised treatment (i.e. treatment emergent) up to week 8.~The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC).~The potential cardiovascular AEs included the following:~Death due to any cause~Non-fatal myocardial infarction~Non-fatal stroke~Unstable angina requiring hospitalisation~Congestive heart failure requiring hospitalisation or medical intervention~Arrhythmias~Hypertension~Hypotension~Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs." (NCT02940860)
Timeframe: Baseline, week 1, 2, and 8

Intervention	Participants (Count of Participants)
Iron Isomaltoside/Ferric Derisomaltose	42
Iron Sucrose	35

Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8

"Efficacy~Results show the number of participants who achieved Hb concentration increase of ≥2 g/dL at any time from week 1 to week 8." (NCT02940860)
Timeframe: Week 1 to week 8

Intervention	Participants (Count of Participants)
Iron Isomaltoside/Ferric Derisomaltose	307
Iron Sucrose	133

Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8

Intervention	Participants (Count of Participants)
Iron Isomaltoside/Ferric Derisomaltose	259
Iron Sucrose	121

Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions

Intervention	Participants (Count of Participants)
Iron Isomaltoside/Ferric Derisomaltose	3
Iron Sucrose	0

Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car

Intervention	miles (Median)
Iron Isomaltoside/Ferric Derisomaltose	19.0
Iron Sucrose	18.0

S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8

"Efficacy~Proportion of subjects reaching the composite endpoint of s-ferritin concentration ≥100 ng/mL and TSAT of 20-50% at any time from week 1 to 8." (NCT02940860)
Timeframe: Week 1 to week 8

Intervention	Participants (Count of Participants)
Iron Isomaltoside/Ferric Derisomaltose	873
Iron Sucrose	388

S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8

"Safety~Results show the number of participants who had s-phosphate <2 mg/dL at any time from baseline to week 1, 2, 4, or 8." (NCT02940860)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	Participants (Count of Participants)
Iron Isomaltoside/Ferric Derisomaltose	32
Iron Sucrose	4

Time to Change in Hb Concentration ≥1 g/dL

"Efficacy~Time to change in Hb concentration ≥1 g/dL.~Subjects who showed Hb concentration increase of ≥1 g/dL (from baseline to week 1, 2, 4, and 8).~For responders, time to Hb response was defined as the scheduled time from baseline until the visit where the first Hb response was measured." (NCT02940860)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	Days (Median)
Iron Isomaltoside/Ferric Derisomaltose	56
Iron Sucrose	56

Time to First Composite Cardiovascular Safety AE

Intervention	Week (Median)
Iron Isomaltoside/Ferric Derisomaltose	NA
Iron Sucrose	NA

Change in Concentration of S-iron From Baseline to Week 1, 2, 4, and 8

"Efficacy~Changes in the concentrations of serum iron (s-iron) from baseline to week 1, 2, 4, and 8." (NCT02940860)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	μg/dL (Mean)
	Week 1	Week 2	Week 4	Week 8
Iron Isomaltoside/Ferric Derisomaltose	34.8	11.1	6.5	7.1
Iron Sucrose	11.1	12.4	10.2	12.4

Change in Fatigue Symptoms From Baseline to Week 1, 2, and 8

Intervention	score on a scale (Mean)
	Week 1	Week 2	Week 8
Iron Isomaltoside/Ferric Derisomaltose	5.04	7.29	9.13
Iron Sucrose	5.01	7.63	9.07

Change in Hb Concentration From Baseline to Week 1, 2, and 4

"Efficacy~Change in Hb concentration from baseline to week 1, 2, and 4." (NCT02940860)
Timeframe: Baseline, week 1, 2, and 4

Intervention	g/dL (Mean)
	Week 1	Week 2	Week 4
Iron Isomaltoside/Ferric Derisomaltose	0.44	0.77	1.08
Iron Sucrose	0.21	0.50	0.90

Change in S-ferritin From Baseline to Weeks 1, 2, 4, and 8

"Efficacy~Changes in s-ferritin from baseline to weeks 1, 2, 4, and 8." (NCT02940860)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	ng/mL (Mean)
	Week 1	Week 2	Week 4	Week 8
Iron Isomaltoside/Ferric Derisomaltose	492.4	381.2	258.4	191.3
Iron Sucrose	183.9	292.4	255.4	187.9

Change in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8

"Efficacy~Changes in transferrin saturation (TSAT) from baseline to week 1, 2, 4, and 8." (NCT02940860)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	percent (Mean)
	Week 1	Week 2	Week 4	Week 8
Iron Isomaltoside/Ferric Derisomaltose	12.10	5.84	4.99	5.10
Iron Sucrose	4.31	5.64	5.59	5.93

Hb Concentration Increase of ≥1 g/dL From Baseline to Week 1, 2, 4, and 8

"Efficacy~Results show Hb responders to the treatment. A subject was considered a Hb responder to a certain week if an increase in Hb of at least 1 g/dL from baseline to the week in question was observed (from baseline to week 1, 2, 4, and 8)." (NCT02940860)
Timeframe: Baseline, week 1, 2, 4, and 8

Intervention	Participants (Count of Participants)
	Responder YES week 1	Responder YES week 2	Responder YES week 4	Responder YES week 8
Iron Isomaltoside/Ferric Derisomaltose	200	339	430	474
Iron Sucrose	78	112	174	226

Health Care Resource Use Questionnaire

"Pharmacoeconomics~Resources used by the health care staff (per administration), measured by the health care resource use questionnaire.~The questionnaire assessed the time used by the health care staff during administration of the investigational product and the administration time (including the observational time). The health care participants included in the evaluation were: investigator, pharmacist, physician, study coordinator, study nurse.~The data for this endpoint show the responses at baseline for both treatment groups.~The frequency of drug administration between the 2 treatment groups is different (i.e. up to a factor 5 more frequent in the iron sucrose treatment group)." (NCT02940860)
Timeframe: Baseline

Intervention	hours (Median)
	Time spent per site staff	Time spent per subject
Iron Isomaltoside/Ferric Derisomaltose	1.17	2.58
Iron Sucrose	1.00	2.33

Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Cost of Public Transport/Taxi And Parking

Intervention	US dollars ($) (Median)
	Cost of public transport/taxi	Cost of parking
Iron Isomaltoside/Ferric Derisomaltose	0.0	0.0
Iron Sucrose	0.0	0.0

Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Participants/Others Who Took Time Off Work to Attend Visits

Intervention	Participants (Count of Participants)
	In employment, YES	Took time off work to attend, YES	Assistance by others to attend visit, YES	Others took time off work to attend, YES
Iron Isomaltoside/Ferric Derisomaltose	152	70	410	82
Iron Sucrose	57	26	197	40

Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Time Spent on Visit/Helping on Visit

Intervention	Hours (Median)
	Time spent on visit	Total time spent helping on visit
Iron Isomaltoside/Ferric Derisomaltose	2.00	2.00
Iron Sucrose	2.00	2.00

Percentage of Fractional Oral Iron Absorption Following Treatment With Daprodustat and rhEPO

Blood samples were collected at indicated time points for analysis of fractional oral iron absorption following treatment with Daprodustat and rhEPO. Adjusted mean and 95 percent (%) confidence interval (CI) has been presented. (NCT03457701)
Timeframe: Up to Day 57

Intervention	Percentage (%) of iron absorbed (Mean)
Daprodustat	20.64
rhEPO	20.62

Period 1 and 2: Change From Baseline in Transferrin Following Treatment With Daprodustat or rhEPO

Blood samples were collected from participants for measurement of transferrin at indicated time points. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	Gram per Liter (g/L) (Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	0.182	0.283	-0.177	0.138
rhEPO	0.145	-0.040	-0.163	-0.352

Periods 1 and 2: Change From Baseline in Erythrocyte Mean Corpuscular Volume Following Treatment With Daprodustat and rhEPO

Blood samples were collected from participants for measurement of erythrocyte mean corpuscular volume at indicated time points. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	Femtoliter (fL) (Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	-0.8	-1.5	2.8	0.3
rhEPO	-0.5	-0.8	-0.3	-0.8

Periods 1 and 2: Change From Baseline in Erythrocytes Following Treatment With Daprodustat and rhEPO

Blood samples were collected from participants for measurement of erythrocytes (red blood cells number) at indicated time points. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	10^12 cells/liter (Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	0.05	-0.13	-0.17	-0.13
rhEPO	0.13	0.13	0.13	0.07

Periods 1 and 2: Change From Baseline in Erythroferrone Following Treatment With Daprodustat and rhEPO

Blood samples were collected from participants for measurement of erythroferrone at indicated time points. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	Microgram per liter (ug/L) (Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	0.135	0.075	0.063	0.032
rhEPO	-0.062	-0.090	-0.068	-0.110

Periods 1 and 2: Change From Baseline in Hematocrit Following Treatment With Daprodustat and rhEPO

Blood samples were collected from participants for measurement of hematocrit at indicated time points. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	Proportion of red blood cells in blood (Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	0.002	-0.017	-0.006	-0.010
rhEPO	0.011	0.009	0.009	0.002

Periods 1 and 2: Change From Baseline in Hemoglobin Following Treatment With Daprodustat and rhEPO

Blood samples were collected from participants for measurement of hemoglobin at indicated time points. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	Grams per liter (g/L) (Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	0.7	-5.0	-5.3	-4.3
rhEPO	2.8	3.5	3.7	2.3

Periods 1 and 2: Change From Baseline in Reticulocyte Hemoglobin Following Treatment of Daprodustat and rhEPO

Blood samples were collected from participants for measurement of reticulocyte hemoglobin at indicated time points. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	Picogram (pg) (Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	0.333	0.250	0.817	1.083
rhEPO	-0.033	0.717	-0.350	-0.117

Periods 1 and 2: Change From Baseline in Reticulocytes Following Treatment With Daprodustat and rhEPO

Blood samples were collected from participants for measurement of reticulocytes number at indicated time points. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	10^12 cells/liter (Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	0.001	0.004	0.004	0.020
rhEPO	0.002	-0.004	-0.005	-0.010

Periods 1 and 2: Change From Baseline in Serum Iron Following Treatment With Daprodustat and rhEPO

Blood samples were collected for measurement of serum iron at indicated time points. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	Micromoles per liter (umol/L) (Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	-1.5	2.5	-1.3	-2.2
rhEPO	1.7	3.3	-3.5	-3.3

Periods 1 and 2: Change From Baseline in Soluble Transferrin Receptor Following Treatment of Daprodustat and rhEPO

Blood samples were collected from participants for measurement of soluble transferrin receptor at indicated time points. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	Milligrams per liter (mg/L) (Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	-0.218	-0.340	-0.338	-0.308
rhEPO	0.063	-0.015	0.227	0.195

Periods 1 and 2: Change From Baseline in Transferrin Saturation Following Treatment With Daprodustat or rhEPO

Blood samples were collected from participants for measurement of transferrin saturation at indicated time points. Transferrin saturation was measured as a percentage and is the ratio of serum iron and total iron-binding capacity multiplied by 100. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	Percentage (%) of transferrin saturation (Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	-5.2	3.0	-5.5	-6.7
rhEPO	3.5	8.2	-4.8	-4.7

Periods 1 and 2: Ratio to Baseline (Day 1) in Hepcidin Following Treatment With Daprodustat and rhEPO

Blood samples were collected from participants for measurement of hepcidin at indicated time points. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. The summary of log transformed ration to baseline on markers of iron status for Hepcidin is presented here. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	Microgram per liter (ug/L) (Geometric Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	0.860	0.916	0.703	0.802
rhEPO	0.904	1.052	1.201	1.306

Periods 1 and 2: Ratio to Baseline in Ferritin Following Treatment With Daprodustat and rhEPO

Blood samples were collected from participants for measurement of ferritin at indicated time points. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits in the associated treatment period. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. The summary of log transformed ration to baseline on markers of iron status for Ferritin is presented here. (NCT03457701)
Timeframe: Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days)

Intervention	Microgram per liter (ug/L) (Geometric Mean)
	Period 1, DAY 14	Period 1, DAY 28	Period 2, DAY 14	Period 2, DAY 28
Daprodustat	1.126	1.109	1.067	1.278
rhEPO	0.937	1.004	0.957	0.911

Change From Baseline in Hemoglobin (Hgb)

(NCT00548249)
Timeframe: two time points: baseline and final evaluation (last post baseline assessment, up to 26 weeks)

Intervention	grams/ deciliter (g/dL) (Mean)
0 µg Iron/dL of Dialysate	-0.177
5 µg Iron/dL of Dialysate	0.258
10 µg Iron/dL of Dialysate	0.462
12 µg Iron/dL of Dialysate	0.173
15 µg Iron/dL of Dialysate	-0.018

Number of Subjects With a Rise in Hemoglobin (Hgb) to 12.6 g/dL or More on Two Separate Occasions Measured One Week Apart.

(NCT00548249)
Timeframe: two separate sessions measured one week apart.

Intervention	Subjects (Number)
0 µg Iron/dL of Dialysate	6
5 µg Iron/dL of Dialysate	6
10 µg Iron/dL of Dialysate	9
12 µg Iron/dL of Dialysate	7
15 µg Iron/dL of Dialysate	8

Number of Subjects With Infection Episodes Requiring Antibiotic or Anti-fungal Therapy in Each Treatment Group.

(NCT00548249)
Timeframe: At each dialysis session for up to 26 weeks

Intervention	Subjects (Number)
0 µg Iron/dL of Dialysate	2
5 µg Iron/dL of Dialysate	1
10 µg Iron/dL of Dialysate	2
12 µg Iron/dL of Dialysate	0
15 µg Iron/dL of Dialysate	1

Percent of Subjects Whose Hemoglobin (Hgb) Decreases by a Total of 1.0 Grams/ Deciliter (g/dL) (or More) From Baseline on Each of Two Successive Measurements.

Efficacy of a Soluble Ferric Pyrophosphate (SFP)-containing dialysate solution in maintaining physiological iron levels during chronic HD, as measured by the percent of subjects whose hgb decreases by a total of 1.0 g/dL (or more) from baseline on each of two successive measurements. Hemoglobin was obtained weekly at the mid-week dialysis treatments and compared to baseline value (average of two hgb measurements obtained at the two consecutive baseline visits prior to randomization). (NCT00548249)
Timeframe: up to 26 weeks

Intervention	Percent of subjects (Number)
0 µg Iron/dL of Dialysate	5
5 µg Iron/dL of Dialysate	6
10 µg Iron/dL of Dialysate	5
12 µg Iron/dL of Dialysate	4
15 µg Iron/dL of Dialysate	10

Reticulocyte Hemoglobin (CHr) Values Every Four Weeks, and at the End of the Subject's Treatment.

Efficacy of SFP administration in dialysate solution as measured by Chr values every four weeks, and at the end of the Subject's Treatment (up to 26 weeks). (NCT00548249)
Timeframe: Every 4 weeks

,,,,

Intervention	pg (Mean)
	Baseline Reticulocyte Hemoglobin	Reticulocyte Hemoglobin/ Week 1	Reticulocyte Hemoglobin/ Week 4	Reticulocyte Hemoglobin/ Week 8	Reticulocyte Hemoglobin/ Week 12	Reticulocyte Hemoglobin/ Week 16	Reticulocyte Hemoglobin/ Week 20	Reticulocyte Hemoglobin/ Week 24	Reticulocyte Hemoglobin/ Week 26	Reticulocyte Hemoglobin/ End of Trial	Reticulocyte Hemoglobin/ Final Evaluation
0 µg Iron/dL of Dialysate	32.55	32.42	32.00	32.14	31.83	31.45	31.13	30.93	30.78	30.06	31.85
10 µg Iron/dL of Dialysate	32.86	32.69	32.69	32.75	32.78	33.05	32.81	32.08	32.20	31.46	32.19
12 µg Iron/dL of Dialysate	32.34	31.87	31.82	31.75	31.82	31.86	30.68	30.53	30.72	30.55	31.65
15 µg Iron/dL of Dialysate	32.64	32.40	32.05	32.35	32.48	32.25	31.64	31.40	30.43	30.11	32.13
5 µg Iron/dL of Dialysate	32.98	32.58	32.27	32.28	32.13	31.95	31.81	31.85	31.32	31.50	31.68

Time in Days for Hgb to Decrease by a Total of > = 1.0 g/dL From Baseline on Each of Two Successive Measurements in Each Treatment Group.

Kaplan-Meier Estimate of Time to First Hgb Decrease by >= 1.0 g/dL (NCT00548249)
Timeframe: Up to 26 weeks

,,,,

Intervention	Days (Number)
	5th Percentile	10th Percentile	15th Percentile	20th Percentile	25th Percentile
0 µg Iron/dL of Dialysate	59	94	94	115	115
10 µg Iron/dL of Dialysate	10	106	106	106	115
12 µg Iron/dL of Dialysate	31	45	115	115	150
15 µg Iron/dL of Dialysate	31	31	38	80	94
5 µg Iron/dL of Dialysate	24	31	66	87	108

Change in Average Total Insulin Dose Per Body Weight

This measure is computed using the average amount of exogenous insulin taken per day for the 3 days prior to the visit. The average insulin use is divided by the subject's weight in kilograms (kg). The need for lower dose(s) of prescribed exogenous insulin while maintaining optimal control of a subject's diabetes reflects improved management of the underlying disease. (NCT00129259)
Timeframe: Baseline (Pre-treatment), Month 24

Intervention	Units of Insulin/kilogram/day (U/kg/day) (Mean)
Anti-CD3 mAb Plus Diabetes Standard of Care Treatment	0.23
Diabetes Standard of Care Treatment	0.35

Change in HbA1c

Glycosylated hemoglobin (HbA1c) is a measure of the average plasma glucose concentration over prolonged periods of time and measures the level of optimal management of underlying disease. (Normal :< 5.7%; pre-diabetes: 5.7% -6.4%; diabetes: 6.5% or higher).A decline in HbA1c from baseline to month 24 signifies an improvement in diabetic control. The goal of treatment: to maintain the HgA1c level as close to normal as possible without frequent occurrence of hypoglycemia. (NCT00129259)
Timeframe: Baseline (Pre-treatment), Month 24

Intervention	Percentage (%) (Mean)
Anti-CD3 mAb Plus Diabetes Standard of Care Treatment	0.129
Diabetes Standard of Care Treatment	0.195

Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT)

C-peptide AUC is computed using the trapezoidal rule and dividing by the interval of time from the 4 hour Mixed Meal Tolerance Test (MMTT) where assessments are taken every 30 minutes after initial assessments 15 minutes apart. A higher C-peptide AUC is desirable as detectable C-peptide is a marker for the ability of the pancreas to produce insulin in response to a MMTT. The baseline data was used to adjust for the C-peptide AUC primary endpoint at 24 months. Missing month 24 C-peptide results are imputed using a conservative scenario. (NCT00129259)
Timeframe: Baseline (Pre-treatment), Month 24

Intervention	pmol/mL (Least Squares Mean)
Anti-CD3 mAb Plus Diabetes Standard of Care Treatment	-0.28
Diabetes Standard of Care Treatment	-0.46

Adherence to Treatment.

Adherence to treatment was calculated as the number of days with at least one opening of the electronic device divided by the total number of monitored days. The device was a MEMS (Medication Event Monitoring System,AARDEX, Europe, Switzerland) (NCT00689793)
Timeframe: 4 weeks

Intervention	percentage of day (Mean)
Oral Treatment of Iron	96
Placebo	96

Aerobic Capacity Using an Indirect Measurement of VO2Max : Chester Step Test

Subjects were asked to step on to and off a 20cm step at a rate set by a metronome. Step rate increased gradually until subject reached her submaximal predicted heart rate. (NCT00689793)
Timeframe: baseline and 4 weeks

Intervention	mLO2/kg/min (Mean)
Oral Treatment of Iron	40.5
Placebo	40.1

Ferritin Change Before and After 4 Weeks of Treatment/Placebo

Level of ferritin measured 4 weeks after randomization (NCT00689793)
Timeframe: baseline and 4 weeks

Intervention	ng/mL (Mean)
Oral Treatment of Iron	28.0
Placebo	12.9

Hemoglobin Variation Before and After Treatment vs Placebo

The level of hemoglobin measured 4 weeks after randomization (NCT00689793)
Timeframe: baseline and 4 weeks

Intervention	g/L (Mean)
Oral Treatment of Iron	135
Placebo	130

Level of Fatigue Before and After Iron Treatment/Placebo, Using a 10 Point Visual Analogue Scale.

"The level of fatigue perceived at baseline and after 4 weeks was scored on a 10-point visual analogue scale ranging from no fatigue=0 to very severe fatigue=10." (NCT00689793)
Timeframe: baseline and 4 weeks

Intervention	centimeter (Mean)
Oral Treatment of Iron	3.4
Placebo	3.5

Response of Iron Supplementation on Mental Disorder

Depression was assessed using the Prime-MD Patient Health Questionnaire (PHQ-9), self-administered by the subject.Diagnosis of depression syndrom was made scoring results of the nine item (range : 0-3). A score >15 (range of total overall scale:0-27) was considered as a depression syndrome. The outcome measure is the number the donors with a depression syndrome at baseline who had a positive response (total score= or <15) after placebo or treatment. (NCT00689793)
Timeframe: baseline and 4 weeks

Intervention	participants (Number)
Oral Treatment of Iron	3
Placebo	4

Extremely Pre-term

Birth before 28 weeks gestation (NCT00860470)
Timeframe: Up to 28 weeks of gestation

Intervention	participants (Number)
Iron and Folate	136
Multiple Micronutrient	106

Infant Mortality Through 6 mo of Age

Infant Mortality to Age 6 months (180 days from birth) (NCT00860470)
Timeframe: 6-months post-birth

Intervention	participants (Number)
Iron and Folate	764
Multiple Micronutrient	741

Low Birth Weight

Birth weight below 2500g (NCT00860470)
Timeframe: Measured at delivery/birth

Intervention	participants (Number)
Iron and Folate	4809
Multiple Micronutrient	4275

Moderate to Late Preterm

Birth between 32 and 37 weeks gestation (NCT00860470)
Timeframe: Between 31 and 38 weeks of gestation

Intervention	participants (Number)
Iron and Folate	2391
Multiple Micronutrient	2113

Neonatal Mortality

Neonatal Mortality (28 days of life) (NCT00860470)
Timeframe: 1 month post-birth

Intervention	participants (Number)
Iron and Folate	625
Multiple Micronutrient	626

Post-neonatal Mortality

Risk of Post-neonatal Mortality (29th -180th day of life) (NCT00860470)
Timeframe: 1-6 months post-birth

Intervention	participants (Number)
Iron and Folate	139
Multiple Micronutrient	115

Preterm Birth

Being born before 37 weeks of gestation (NCT00860470)
Timeframe: Up to 37 weeks of gestation

Intervention	participants (Number)
Iron and Folate	2912
Multiple Micronutrient	2510

Small for Gestation Age

Small for Gestational Age defined as birth weight <10th percentile of a standard reference (Alexander GR, Himes JH, Kaufman RB, et al. Obstet Gynecol. 1996;87(2):163-68). (NCT00860470)
Timeframe: At delivery/birth

Intervention	participants (Number)
Iron and Folate	6479
Multiple Micronutrient	6405

Still Birth Rates

Stillbirth (born >=24 weeks without breathing, crying, or moving limbs). (NCT00860470)
Timeframe: 24 weeks gestation to delivery

Intervention	participants (Number)
Iron and Folate	716
Multiple Micronutrient	648

Very Pre-term

Birth between 28 and 32 weeks of gestation (NCT00860470)
Timeframe: Between 27 and 33 weeks of gestation

Intervention	participants (Number)
Iron and Folate	385
Multiple Micronutrient	291